Literature DB >> 26898611

Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer.

Simone Tönnies1, Mario Tönnies1, Jens Kollmeier2, Torsten T Bauer2, Gregor J Förster3, Dirk Kaiser1, Klaus-Dieter Wernecke4, Joachim Pfannschmidt5.   

Abstract

OBJECTIVES: Surgery has been available for the treatment of mono-metastatic, non-small cell lung cancer (NSCLC) and promising overall survival was observed in some retrospective studies with selected patients. This study investigated whether the preoperative 18-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) scan influences survival in this patient group. Furthermore we tried to identify other prognostic factors associated with survival and aimed to clarify if synchronous metastases are different from metachronous disease.
METHODS: Between 1994 and 2012, 181 patients underwent resection for solitary metastases. Sixty-six patients underwent surgery after an initial FDG-PET/CT scan, whereas 115 patients underwent conventional preoperative staging by a spiral CT scan.
RESULTS: The overall 5-year survival rate was 38.8%. The 5-year survival rates after preoperative evaluation by FDG-PET/CT and by conventional CT were 58% and 33%, respectively (p=0.01). A higher 5-year survival rate was observed in patients without thoracic lymph node involvement (pN0: 44% vs. pN1-3: 33%, p=0.028). In patients with a solitary pulmonary metastasis, we observed a 5-year survival rate of 45.7%, whereas in patients with extrapulmonary metastases, the 5-year survival rate was 27.1% (p=0.001). In patients with a locally limited primary lung cancer according to the pT descriptor, we observed a 5-year survival rate of 53.1%, whereas in patients with a pT>1 descriptor, the 5-year survival rate was 33.6% (p=0.016). By multivariate analyses, we showed that preoperative FDG-PET/CT evaluation, no thoracic lymph node metastases, and sole pulmonary metastatic disease were favorable predictors of survival, whereas the time of metastasis (synchronous vs. metachronous) and maximum standardized uptake value was not.
CONCLUSIONS: We conclude that resection of the primary tumor and metastasectomy for mono-metastatic NSCLC can be performed after a comprehensive evaluation with FDG-PET/CT. N-stage and the site of the oligometastases have a significant influence on overall survival.
Copyright © 2016. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Metastasectomy; Non-small cell lung cancer; Oligometastases; PET/CT; Survival rate

Mesh:

Substances:

Year:  2015        PMID: 26898611     DOI: 10.1016/j.lungcan.2015.12.008

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  11 in total

1.  Expanding the knowledge of oligometastatic disease-but uncertainties remain significant.

Authors:  Joachim Pfannschmidt
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

Review 2.  Surgical approach in oligometastatic non-small cell lung cancer.

Authors:  Davide Patrini; Nikolaos Panagiotopoulos; Benedetta Bedetti; Sofoklis Mitsos; Roberto Crisci; Piergiorgio Solli; Luca Bertolaccini; Marco Scarci
Journal:  Ann Transl Med       Date:  2018-03

Review 3.  The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review.

Authors:  Lawek Berzenji; Sophie Debaenst; Jeroen M H Hendriks; Suresh Krishan Yogeswaran; Patrick Lauwers; Paul E Van Schil
Journal:  Transl Lung Cancer Res       Date:  2021-07

Review 4.  Surgical management of oligometastatic non-small cell lung cancer.

Authors:  Nuria M Novoa; Gonzalo Varela; Marcelo F Jiménez
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 5.  Defining oligometastatic non-small cell lung cancer: concept versus biology, a literature review.

Authors:  Jill F Mentink; Marthe S Paats; Daphne W Dumoulin; Robin Cornelissen; Joris B W Elbers; Alexander P W M Maat; Jan H von der Thüsen; Anne-Marie C Dingemans
Journal:  Transl Lung Cancer Res       Date:  2021-07

6.  Enhanced glucose metabolism mediated by CD147 is associated with 18 F-FDG PET/CT imaging in lung adenocarcinoma.

Authors:  Yufan Zhang; Jianjing Liu; Yunchuan Sun; Xiaozhou Yu; Jian Wang; Dong Dai; Yanjia Zhu; Xiuyu Song; Lei Zhu; Xiaofeng Li; Wengui Xu
Journal:  Thorac Cancer       Date:  2020-03-11       Impact factor: 3.500

7.  Cost-effectiveness analysis of positron-emission tomography-computed tomography in preoperative staging for nonsmall-cell lung cancer with resected monometastatic disease.

Authors:  Xiaohui Zeng; Liubao Peng; Chongqing Tan; Yunhua Wang
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

Review 8.  Radiotherapy for Oligometastatic Lung Cancer.

Authors:  Derek P Bergsma; Joseph K Salama; Deepinder P Singh; Steven J Chmura; Michael T Milano
Journal:  Front Oncol       Date:  2017-09-19       Impact factor: 6.244

Review 9.  Management of oligometastatic non-small cell lung cancer patients: Current controversies and future directions.

Authors:  Felipe Couñago; Javier Luna; Luis Leonardo Guerrero; Blanca Vaquero; María Cecilia Guillén-Sacoto; Teresa González-Merino; Begoña Taboada; Verónica Díaz; Belén Rubio-Viqueira; Ana Aurora Díaz-Gavela; Francisco José Marcos; Elia Del Cerro
Journal:  World J Clin Oncol       Date:  2019-10-24

Review 10.  Imaging of Oligometastatic Disease.

Authors:  Naik Vietti Violi; Rami Hajri; Laura Haefliger; Marie Nicod-Lalonde; Nicolas Villard; Clarisse Dromain
Journal:  Cancers (Basel)       Date:  2022-03-10       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.